A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells
Authors
Keywords
-
Journal
Scientific Reports
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-19
DOI
10.1038/s41598-021-90096-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
- (2020) Adi Diab et al. Cancer Discovery
- The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques
- (2020) Gabriela M. Webb et al. PLoS Pathogens
- ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
- (2020) Jared E Lopes et al. Journal for ImmunoTherapy of Cancer
- 1027MO ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumours (ARTISTRY-1)
- (2020) U.N. Vaishampayan et al. ANNALS OF ONCOLOGY
- Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors
- (2020) F. Janku et al. EUROPEAN JOURNAL OF CANCER
- De novo design of potent and selective mimics of IL-2 and IL-15
- (2019) Daniel-Adriano Silva et al. NATURE
- Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies
- (2019) Starlynn C. Clarke et al. Frontiers in Immunology
- IL-15 by continuous i.v. infusion to adult patients with solid tumors in a Phase I trial induced dramatic NK cell subset expansion
- (2019) Kevin C Conlon et al. CLINICAL CANCER RESEARCH
- Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation
- (2019) Patrizia Murer et al. New Biotechnology
- 89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding
- (2018) Emilie M.J. van Brummelen et al. Oncotarget
- Prospects of IL-2 in Cancer Immunotherapy
- (2018) Hani Choudhry et al. Biomed Research International
- Sequence-Based Discovery Demonstrates That Fixed Light Chain Human Transgenic Rats Produce a Diverse Repertoire of Antigen-Specific Antibodies
- (2018) Katherine E. Harris et al. Frontiers in Immunology
- Abstract 5565: Potency-reduced IL15/IL15Rα heterodimeric Fc-fusions display enhanced in vivo activity through increased exposure
- (2018) Matthew J. Bernett et al. CANCER RESEARCH
- Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
- (2017) Christian Klein et al. OncoImmunology
- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
- (2016) D. H. Charych et al. CLINICAL CANCER RESEARCH
- Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2
- (2016) N. Arenas-Ramirez et al. Science Translational Medicine
- Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model
- (2015) Dimitrios Mathios et al. INTERNATIONAL JOURNAL OF CANCER
- Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
- (2015) Kevin C. Conlon et al. JOURNAL OF CLINICAL ONCOLOGY
- Interleukin-2: Biology, Design and Application
- (2015) Natalia Arenas-Ramirez et al. TRENDS IN IMMUNOLOGY
- The IL-2 cytokine family in cancer immunotherapy
- (2014) Geok Choo Sim et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics
- (2014) Johan J.F. Verhoef et al. DRUG DISCOVERY TODAY
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program
- (2014) Roxanne Payne et al. Journal for ImmunoTherapy of Cancer
- Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor Su/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma
- (2013) W. Xu et al. CANCER RESEARCH
- IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients
- (2013) Geok Choo Sim et al. JOURNAL OF CLINICAL INVESTIGATION
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer
- (2013) Claudia C. Preston et al. PLoS One
- A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans
- (2012) Babette Wolf et al. CYTOKINE
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
- (2012) Aron M. Levin et al. NATURE
- Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data
- (2011) Rong Deng et al. mAbs
- Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis
- (2011) David Saadoun et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
- (2011) John Koreth et al. NEW ENGLAND JOURNAL OF MEDICINE
- gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
- (2011) Douglas J. Schwartzentruber et al. NEW ENGLAND JOURNAL OF MEDICINE
- The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
- (2010) Manfred Johannsen et al. EUROPEAN JOURNAL OF CANCER
- Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response
- (2010) Ofer Feinerman et al. Molecular Systems Biology
- Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
- (2010) C. Krieg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intrachain disulfide bond in the core hinge region of human IgG4
- (2010) James W. Bloom et al. PROTEIN SCIENCE
- Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2
- (2008) C. Schliemann et al. BLOOD
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search